{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:49:09Z","timestamp":1783111749631,"version":"3.54.6"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP15mk0101059"],"award-info":[{"award-number":["JP15mk0101059"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18mk0101104"],"award-info":[{"award-number":["JP18mk0101104"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21mk0101194"],"award-info":[{"award-number":["JP21mk0101194"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP 24mk0121283"],"award-info":[{"award-number":["JP 24mk0121283"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejps.2025.107357","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:06:36Z","timestamp":1761897996000},"page":"107357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Evaluation of anti-drug antibodies against therapeutic monoclonal antibodies and related product in Japanese patients with rheumatoid arthritis and their clinical impact"],"prefix":"10.1016","volume":"216","author":[{"given":"Hiroko","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Tsukagoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Ishii-Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Masuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107357_bib0001","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jcph.826","article-title":"Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA","volume":"57","author":"Abdallah","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107357_bib0002","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejps.2025.107357_bib0003","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-inhibitors","volume":"11","author":"Atiqi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2025.107357_bib0004","first-page":"688","article-title":"Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study","volume":"57","author":"Balsa","year":"2018","journal-title":"Rheumatol. (United Kingdom)"},{"key":"10.1016\/j.ejps.2025.107357_bib0005","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against Adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMa"},{"key":"10.1016\/j.ejps.2025.107357_bib0006","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.TP.0000073809.65502.8F","article-title":"Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti\u2013interleukin-2 receptor monoclonal antibody basiliximab","volume":"76","author":"Baudouin","year":"2003","journal-title":"Transplantation."},{"key":"10.1016\/j.ejps.2025.107357_bib0007","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/joim.13495","article-title":"Risk factors for anti-drug antibody formation to infliximab: secondary analyses of a randomised controlled trial","volume":"292","author":"Brun","year":"2022","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejps.2025.107357_bib0008","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/annrheumdis-2016-210297","article-title":"Low immunogenicity of tocilizumab in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2025.107357_bib0009","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1208\/s12248-012-9340-y","article-title":"Immunogenicity to therapeutic proteins: impact on PK\/PD and efficacy","volume":"14","author":"Chirmule","year":"2012","journal-title":"AAPS. J."},{"key":"10.1016\/j.ejps.2025.107357_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/ard.2006.057745","article-title":"Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2025.107357_bib0011","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.55730\/1300-0144.5914","article-title":"The relationship between drug induced immunogenicity and hypersensitivity reactions and skin tests related to infliximab, etanercept and adalimumab in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"54","author":"Do\u011fanci","year":"2024","journal-title":"Turk. J. Med. Sci."},{"key":"10.1016\/j.ejps.2025.107357_bib0012","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/annrheumdis-2015-207588","article-title":"A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy","volume":"76","author":"Emery","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2025.107357_bib0014","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1136\/annrheumdis-2012-202220","article-title":"The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis","volume":"72","author":"Garc\u00eas","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2025.107357_bib0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40629-020-00126-6","article-title":"Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events","volume":"29","author":"G\u00fclsen","year":"2020","journal-title":"Allergo J. Int."},{"key":"10.1016\/j.ejps.2025.107357_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2017.05.030","article-title":"Perspectives on subcutaneous route of administration as an immunogenicity risk factor for therapeutic proteins","author":"Hamuro","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107357_bib0017","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs."},{"key":"10.1016\/j.ejps.2025.107357_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003348","article-title":"Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: a prospective multicohort study of the ABIRISK consortium","volume":"17","author":"H\u00e4ssler","year":"2020","journal-title":"PLoS. Med."},{"key":"10.1016\/j.ejps.2025.107357_bib0019","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3109\/s10165-011-0567-8","article-title":"Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis","volume":"22","author":"Hoshino","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.ejps.2025.107357_bib0020","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","article-title":"Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients","volume":"71","author":"Jamnitski","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2025.107357_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2153410","article-title":"Antibodies to watch in 2023","volume":"15","author":"Kaplon","year":"2023","journal-title":"MAbs."},{"key":"10.1016\/j.ejps.2025.107357_bib0022","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1208\/s12248-024-00953-3","article-title":"Evaluating the performance of two automated anti-drug antibodies assays for Infliximab and Adalimumab without acid dissociation","volume":"26","author":"Karsten","year":"2024","journal-title":"AAPS. J."},{"key":"10.1016\/j.ejps.2025.107357_bib0023","doi-asserted-by":"crossref","DOI":"10.1586\/1744666X.2015.1090312","article-title":"Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13)","author":"Kim","year":"2015","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.ejps.2025.107357_bib0024","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2025.107357_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to biotherapeutics - the role of anti-drug immune complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2025.107357_bib0026","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/archdermatol.2009.347","article-title":"Extent and clinical consequences of antibody formation against Adalimumab in patients with plaque psoriasis","volume":"146","author":"Lecluse","year":"2010","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.ejps.2025.107357_bib0027","article-title":"Identification of HLA-DRB1 association to adalimumab immunogenicity","volume":"13","author":"Liu","year":"2018","journal-title":"PLoS. One"},{"key":"10.1016\/j.ejps.2025.107357_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejps.2025.107357_bib0029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/RHU.0000000000000612","article-title":"Incidence of antidrug antibodies in rheumatoid arthritis patients from Argentina treated with Adalimumab, Etanercept, or Infliximab in a real-world setting","volume":"24","author":"Maid","year":"2018","journal-title":"J. Clin. Rheumatol.: Practical Reports Rheum. Musculoskel. Diseases"},{"key":"10.1016\/j.ejps.2025.107357_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10787-012-0123-y","article-title":"Rheumatoid arthritis and the era of biologic therapy","volume":"20","author":"Malaviya","year":"2012","journal-title":"Inflammopharmacology."},{"key":"10.1016\/j.ejps.2025.107357_bib0031","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/rheumatology\/kead690","article-title":"Early monitoring of anti-infliximab antibodies by drug-tolerant assay predicts later immunogenicity and drug survival in rheumatic diseases","volume":"64","author":"Mart\u00ednez-Feito","year":"2025","journal-title":"Rheumatology."},{"key":"10.1016\/j.ejps.2025.107357_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000757","article-title":"Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study","volume":"4","author":"Matucci-Cerinic","year":"2018","journal-title":"RMD. Open."},{"key":"10.1016\/j.ejps.2025.107357_bib0033","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3389\/fimmu.2020.00589","article-title":"What is the clinical relevance of TNF inhibitor immunogenicity in the management of patients with rheumatoid arthritis?","volume":"11","author":"Mehta","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2025.107357_bib0034","article-title":"The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study","volume":"12","author":"Moots","year":"2017","journal-title":"PLoS. One"},{"key":"10.1016\/j.ejps.2025.107357_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.885672","article-title":"Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients","volume":"13","author":"Mosch","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2025.107357_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099453","article-title":"Protective effect of the HLA-DRB1*13:02 allele in Japanese rheumatoid arthritis patients","volume":"9","author":"Oka","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.ejps.2025.107357_bib0037","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1995929","article-title":"The impact of immunogenicity on therapeutic antibody pharmacokinetics: a preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance","volume":"13","author":"Opolka-Hoffmann","year":"2021","journal-title":"MAbs."},{"key":"10.1016\/j.ejps.2025.107357_bib0038","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.3390\/jcm12093271","article-title":"Anti-drug antibodies in the biological therapy of autoimmune rheumatic diseases","volume":"12","author":"Pizano-Martinez","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejps.2025.107357_bib0039","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.12688\/f1000research.18688.1","article-title":"Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies","volume":"8","author":"Senolt","year":"2019","journal-title":"F1000Res."},{"key":"10.1016\/j.ejps.2025.107357_bib0040","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","article-title":"Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products","volume":"48","author":"Shankar","year":"2008","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2025.107357_bib0041","doi-asserted-by":"crossref","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","author":"Strand","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejps.2025.107357_bib0042","doi-asserted-by":"crossref","DOI":"10.1038\/nrrheum.2010.154","article-title":"The Japanese experience with biologic therapies for rheumatoid arthritis","author":"Takeuchi","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejps.2025.107357_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1457993","article-title":"Antidrug antibodies to adalimumab do not associate with immunologically related adverse events","volume":"15","author":"Tourdot","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2025.107357_bib0044","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","article-title":"Mechanisms of therapeutic antitumor monoclonal antibodies","volume":"81","author":"Tsao","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2025.107357_bib0045","doi-asserted-by":"crossref","unstructured":"United States Pharmacopeia, 2023. \u30081106\u3009 Immunogenicity assays\u2014Design and validation of immunoassays to detect anti-drug antibodies. https:\/\/doi.org\/10.31003\/USPNF_M99825_02_01. (accessed 12 September 2025).","DOI":"10.31003\/USPNF_M99825_02_01"},{"key":"10.1016\/j.ejps.2025.107357_bib0048","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","article-title":"The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies","volume":"11","author":"Vaisman-Mentesh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2025.107357_bib0049","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1208\/s12248-015-9857-y","article-title":"Evaluating and reporting the immunogenicity impacts for biological products\u2014A clinical pharmacology perspective","volume":"18","author":"Wang","year":"2016","journal-title":"AAPS. J."},{"key":"10.1016\/j.ejps.2025.107357_bib0050","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/apt.15563","article-title":"HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease","volume":"51","author":"Wilson","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107357_bib0051","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1208\/s12248-020-00518-0","article-title":"Comparison of the ELISA and ECL Assay for Vedolizumab anti-drug antibodies: assessing the impact on pharmacokinetics and safety outcomes of the phase 3 GEMINI trials","volume":"23","author":"Wyant","year":"2021","journal-title":"AAPS. J."},{"key":"10.1016\/j.ejps.2025.107357_bib0052","article-title":"HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis","author":"Yap","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2025.107357_bib0053","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13075-020-2137-y","article-title":"Identification of molecules associated with response to abatacept in patients with rheumatoid arthritis","volume":"22","author":"Yokoyama-Kokuryo","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejps.2025.107357_bib0054","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejps.2025.107357_bib0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1208\/s12248-012-9408-8","article-title":"Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics","volume":"15","author":"Zhou","year":"2013","journal-title":"AAPS. J."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T19:22:10Z","timestamp":1766776930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":52,"alternative-id":["S0928098725003549"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107357","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of anti-drug antibodies against therapeutic monoclonal antibodies and related product in Japanese patients with rheumatoid arthritis and their clinical impact","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107357"}}